Literature DB >> 30612778

MFG-E8 overexpression is associated with poor prognosis in breast cancer patients.

Lifeng Yu1, Lin Zhao1, Zhen Jia1, Jia Bi1, Qian Wei1, Xinyue Song1, Longyang Jiang1, Shu Lin1, Minjie Wei2.   

Abstract

BACKGROUND: MFG-E8(Milk fat globule-EGF factor 8), a secreted glycoprotein, plays an exceptional role in various diseases. MFG-E8 overexpression is found in a variety of cancers. However, it remains unclear whether MFG-E8 overexpression is associated with the clinicopathological characteristics and prognosis of human breast cancer.
MATERIALS AND METHODS: In this study, we detected the expression and localization of MFG-E8 protein in breast cancer and cancer-adjacent tissues using immunohistochemical staining, Western blot analysis and immunofluorescence. We analyzed the association between MFG-E8 expression and clinical characteristics and outcomes of breast cancer patients with different HR and HER2 statuses.
RESULTS: Our results confirmed that MFG-E8 expression increased significantly in breast cancer compared with cancer-adjacent tissues by immunohistochemical staining (P <  0.001). Similarly, the Western blot results further confirmed the increased expression of MFG-E8 in breast cancer compared with cancer-adjacent tissues (P =  0.001). Immunofluorescence staining showed that MFG-E8 was mainly localized in the cytoplasm and membrane of tumor cells, consistent with the immunohistochemical staining results. The high expression levels of MFG-E8 showed a greater association with lymph node metastasis, TNM stage and histological grade (P < 0.001). Moreover, high MFG-E8 expression was related to a shortened overall survival (OS) (P <  0.001) and disease-free survival (DFS) (P <  0.001). Bioinformatics analysis with a Kaplan-Meier plotter also demonstrated a strong association of MFG-E8 mRNA overexpression with a short OS and DFS compared with low MFG-E8 expression (P =  0.040, P =  0.005).
CONCLUSIONS: Our findings indicate that MFG-E8 may be a potential marker for poor prognosis and survival in breast cancer.
Copyright © 2019 Elsevier GmbH. All rights reserved.

Entities:  

Keywords:  Breast cancer; Clinicopathological characteristics; MFG-E8; Prognosis

Mesh:

Substances:

Year:  2018        PMID: 30612778     DOI: 10.1016/j.prp.2018.12.036

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  5 in total

1.  Transcriptional Repression by FoxM1 Suppresses Tumor Differentiation and Promotes Metastasis of Breast Cancer.

Authors:  Dragana Kopanja; Vaibhav Chand; Eilidh O'Brien; Nishit K Mukhopadhyay; Maria P Zappia; Abul B M M K Islam; Maxim V Frolov; Bradley J Merrill; Pradip Raychaudhuri
Journal:  Cancer Res       Date:  2022-07-05       Impact factor: 13.312

2.  High Levels of MFG-E8 Confer a Good Prognosis in Prostate and Renal Cancer Patients.

Authors:  Karen Geoffroy; Patrick Laplante; Sylvie Clairefond; Feryel Azzi; Dominique Trudel; Jean-Baptiste Lattouf; John Stagg; Fred Saad; Anne-Marie Mes-Masson; Marie-Claude Bourgeois-Daigneault; Jean-François Cailhier
Journal:  Cancers (Basel)       Date:  2022-06-04       Impact factor: 6.575

Review 3.  Lactadherin: From a Well-Known Breast Tumor Marker to a Possible Player in Extracellular Vesicle-Mediated Cancer Progression.

Authors:  Eduardo Durán-Jara; Tamara Vera-Tobar; Lorena De Lourdes Lobos-González
Journal:  Int J Mol Sci       Date:  2022-03-31       Impact factor: 5.923

4.  Inframe insertion and splice site variants in MFGE8 associate with protection against coronary atherosclerosis.

Authors:  Sanni E Ruotsalainen; Ida Surakka; Nina Mars; Juha Karjalainen; Mitja Kurki; Masahiro Kanai; Kristi Krebs; Sarah Graham; Pashupati P Mishra; Binisha H Mishra; Juha Sinisalo; Priit Palta; Terho Lehtimäki; Olli Raitakari; Lili Milani; Yukinori Okada; Aarno Palotie; Elisabeth Widen; Mark J Daly; Samuli Ripatti
Journal:  Commun Biol       Date:  2022-08-17

5.  Down-regulation of CCL17 in cancer-associated fibroblasts inhibits cell migration and invasion of breast cancer through ERK1/2 pathway.

Authors:  Junjie Li; Chunli Yang; Jingshi Yang; Liqun Zou
Journal:  Cancer Manag Res       Date:  2019-08-07       Impact factor: 3.989

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.